Pharmacosurveillance in Juvenile Idiopathic Arthritis

Natalie J Shiff; Timothy Beukelman

doi:10.1016/j.rdc.2021.07.012

Pharmacosurveillance in Juvenile Idiopathic Arthritis

Rheum Dis Clin North Am. 2021 Nov;47(4):643-653. doi: 10.1016/j.rdc.2021.07.012. Epub 2021 Sep 2.

Authors

Natalie J Shiff¹, Timothy Beukelman²

Affiliations

¹ Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Room 3250 - East Wing - Health Sciences Boulevard, 104 Clinic Place, Saskatoon, Saskatchewan S7N 2Z4, Canada.
² Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, 1600 7th Avenue South, CPPN G10, Birmingham, AL 35233, USA. Electronic address: tbeukelman@peds.uab.edu.

PMID: 34635296
DOI: 10.1016/j.rdc.2021.07.012

Abstract

The advent of biologic disease-modifying antirheumatic drugs targeting specific cytokines or cell-cell interactions has dramatically changed the outlook of patients with juvenile idiopathic arthritis. However, safety concerns remain around the use of therapeutic agents for children with juvenile idiopathic arthritis. Foremost among these are the risks of serious infections and malignancy. This article provides an overview of methodologies for pharmacosurveillance in juvenile idiopathic arthritis, including spontaneous reporting systems and the use of diverse data sources, such as electronic health records, administrative claims, and clinical registries. The risks of infections and malignancies are then briefly reviewed.

Keywords: Biologics; JIA; Pediatric rheumatology; Pharmacosurveillance.

Publication types

Review

MeSH terms

Antirheumatic Agents* / adverse effects
Arthritis, Juvenile* / drug therapy
Arthritis, Juvenile* / epidemiology
Biological Products* / therapeutic use
Humans
Registries
Treatment Outcome

Substances

Antirheumatic Agents
Biological Products